SABS
Income statement / Annual
Last year (2024), SAB Biotherapeutics, Inc.'s total revenue was $1.32 M,
a decrease of 40.96% from the previous year.
In 2024, SAB Biotherapeutics, Inc.'s net income was -$34.11 M.
See SAB Biotherapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$1.32 M |
$2.24 M |
$23.90 M |
$60.88 M |
$55.24 M |
$3.44 M |
| Cost of Revenue |
$4.79 M
|
$3.75 M
|
$3.29 M
|
$1.65 M
|
$0.00
|
$0.00
|
| Gross Profit |
-$3.47 M
|
-$1.51 M
|
$20.61 M
|
$59.22 M
|
$55.24 M
|
$3.44 M
|
| Gross Profit Ratio |
-2.62
|
-0.67
|
0.86
|
0.97
|
1
|
1
|
| Research and Development Expenses |
$30.25 M
|
$16.52 M
|
$36.44 M
|
$57.18 M
|
$27.91 M
|
$8.02 M
|
| General & Administrative Expenses |
$13.98 M
|
$23.80 M
|
$16.38 M
|
$17.09 M
|
$6.77 M
|
$4.10 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.98 M
|
$23.80 M
|
$16.38 M
|
$17.09 M
|
$6.77 M
|
$4.10 M
|
| Other Expenses |
-$70.00
|
-$3.75 M
|
-$3.29 M
|
-$1.65 M
|
$0.00
|
-$1.00 K
|
| Operating Expenses |
$44.23 M
|
$36.57 M
|
$49.53 M
|
$72.62 M
|
$34.68 M
|
$12.12 M
|
| Cost And Expenses |
$44.23 M
|
$40.31 M
|
$52.82 M
|
$74.27 M
|
$34.68 M
|
$12.12 M
|
| Interest Income |
$1.29 M
|
$584.97 K
|
$71.07 K
|
$23.12 K
|
$26.13 K
|
$113.13 K
|
| Interest Expense |
$318.40 K
|
$315.28 K
|
$301.58 K
|
$294.46 K
|
$469.15 K
|
$428.48 K
|
| Depreciation & Amortization |
$4.79 M
|
$3.75 M
|
$3.29 M
|
$1.65 M
|
$548.18 K
|
$323.41 K
|
| EBITDA |
-$28.99 M |
-$38.13 M |
-$15.12 M |
-$15.20 M |
$21.14 M |
-$8.23 M |
| EBITDA Ratio |
-21.93
|
-17.03
|
-0.63
|
-0.25
|
0.38
|
-2.39
|
| Operating Income Ratio |
-32.46
|
-17.01
|
-1.21
|
-0.22
|
0.37
|
-2.52
|
| Total Other Income/Expenses Net |
$8.81 M
|
-$4.12 M
|
$10.20 M
|
-$3.75 M
|
-$439.00 K
|
-$313.00 K
|
| Income Before Tax |
-$34.11 M
|
-$42.19 M
|
-$18.72 M
|
-$17.15 M
|
$20.12 M
|
-$8.99 M
|
| Income Before Tax Ratio |
-25.8
|
-18.85
|
-0.78
|
-0.28
|
0.36
|
-2.61
|
| Income Tax Expense |
$0.00
|
$0.00
|
$25.63 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$34.11 M
|
-$42.19 M
|
-$18.74 M
|
-$17.15 M
|
$20.12 M
|
-$8.99 M
|
| Net Income Ratio |
-25.8
|
-18.85
|
-0.78
|
-0.28
|
0.36
|
-2.61
|
| EPS |
-3.68 |
-7.64 |
-4.31 |
-3.94 |
4.63 |
-0.22 |
| EPS Diluted |
-3.68 |
-7.64 |
-4.31 |
-6.3 |
7.45 |
-0.22 |
| Weighted Average Shares Out |
$9.26 M
|
$5.52 M
|
$4.35 M
|
$4.35 M
|
$4.35 M
|
$4.35 M
|
| Weighted Average Shares Out Diluted |
$9.26 M
|
$5.52 M
|
$4.35 M
|
$2.73 M
|
$2.70 M
|
$4.35 M
|
| Link |
|
|
|
|
|
|
